Coherus Announces Toripalimab Data at 2023 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics

— Data demonstrate preclinical potent T cell activation and differentiated mechanism of action and enhanced clinical efficacy irrespective of PD-L1 status when administered in combination with...

Related Keywords

Boston ,Massachusetts ,United States ,Canada ,United Kingdom ,China ,Jodi Sievers ,Junshi Biosciences ,Theresa Lavallee ,Coherus Biosciences ,Shanghai Junshi Biosciences Co Ltd ,European Medicines Agency ,Convention Center ,Exchange Commission ,Regulatory Agency ,Nasdaq ,Globenewswire Inc ,Drug Administration ,Coherus Biosciences Inc ,Corporate Communications ,International Conference On Molecular ,Molecular Targets ,Cancer Therapeuticsbeing ,Poster Session ,Exhibit Hall ,Medicines Agency ,Breakthrough Therapy ,Fast Track ,Orphan Drug ,Southeast Asia ,Surface Oncology ,Biologics License Application ,Private Securities Litigation Reform Act ,Coheru Quarterly Report ,Contact Information ,Markets ,